GA_P advises Oryzon Genomics in its new capital increase

Gómez-Acebo & Pombo has advised Oryzon Genomics, a biotechnology company whose shares are listed on the Continuous Market, in its capital increase through the issue of more than 12.7 million new ordinary shares at a price of 2.35 euros per share, increasing the company’s capital by 30 million euros.

The transaction was carried out through an accelerated bookbuild offering.

Oryzon will use the proceeds to strengthen its financial structure, prepare for a Nasdaq listing and expand its clinical programmes in neuroscience and oncology.

The GA_P team was formed by Augusto Piñel, Jacobo Palanca and Irene Carreño Uría, partner and associates of the Corporate and Capital Markets team.

Ver noticia